Literature DB >> 29862158

Severe bacterial sepsis results in delayed diagnosis of tuberculous lymphadenitis in a rheumatoid arthritis patient treated with adalimumab.

Soichiro Sawamura1, Takamitsu Makino1, Takamitsu Johno1, Junji Yamashita1, Daisuke Niimori1, Satoshi Fukushima1, Hironobu Ihn1.   

Abstract

Although tumor necrosis factor (TNF)-α inhibitors are effective in patients with rheumatoid arthritis (RA), an increased risk of infections often becomes a serious problem. It is well known that TNF-α inhibitors increase the risk of tuberculosis, but extrapulmonary tuberculosis often induced by them is difficult to diagnose using routine imaging examinations. We described a case of delayed diagnosis of a tuberculous lymphadenitis in a patient with RA treated with TNF-α inhibitor because of the complications of severe bacterial sepsis. In this case, rescreening with the interferon-γ release assay and excisional biopsy were useful in confirming the diagnosis of extrapulmonary tuberculosis. In the case we presented, she had other risk factors, that is, advanced age at the start of anti- TNF-α treatment or concomitant use of corticosteroid, might contribute to the development of complex infections. We should keep in mind that careful follow-up and appropriate examinations are necessary in caring for patients administering immunosuppressive treatments including anti- TNF-α drugs.

Entities:  

Keywords:  Tumor necrosis factor-α; extrapulmonary tuberculosis; interferon-γ release assay; septic shock

Year:  2018        PMID: 29862158      PMCID: PMC5982623          DOI: 10.5582/irdr.2018.01050

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  10 in total

Review 1.  Anti-TNF treatment in rheumatoid arthritis.

Authors:  Janina Geiler; Maya Buch; Michael F McDermott
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

2.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

3.  The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis.

Authors:  Giovanna Cuomo; Virginia D’Abrosca; Daniela Iacono; Ilenia Pantano
Journal:  Clin Rheumatol       Date:  2016-11-05       Impact factor: 2.980

4.  Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay.

Authors:  Der-Yuan Chen; Gwan-Han Shen; Yi-Ming Chen; Hsin-Hua Chen; Chia-Wei Hsieh; Joung-Liang Lan
Journal:  Ann Rheum Dis       Date:  2011-10-21       Impact factor: 19.103

5.  Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.

Authors:  Dimitrios Vassilopoulos; Stamatoula Tsikrika; Chrisoula Hatzara; Varvara Podia; Anna Kandili; Nikolaos Stamoulis; Emilia Hadziyannis
Journal:  Clin Vaccine Immunol       Date:  2011-10-12

Review 6.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Authors:  Michael A Gardam; Edward C Keystone; Richard Menzies; Steven Manners; Emil Skamene; Richard Long; Donald C Vinh
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

7.  Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients.

Authors:  Ennio Giulio Favalli; Francesca Desiati; Fabiola Atzeni; Piercarlo Sarzi-Puttini; Roberto Caporali; Francesca Bobbio Pallavicini; Roberto Gorla; Matteo Filippini; Antonio Marchesoni
Journal:  Autoimmun Rev       Date:  2008-11-18       Impact factor: 9.754

8.  Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.

Authors:  Khaldoon M Alawneh; Mahmoud H Ayesh; Basheer Y Khassawneh; Salwa Shihadeh Saadeh; Mahmoud Smadi; Khaldoun Bashaireh
Journal:  Biologics       Date:  2014-04-22

9.  Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Authors:  W G Dixon; K L Hyrich; K D Watson; M Lunt; J Galloway; A Ustianowski; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2009-10-22       Impact factor: 19.103

10.  Adalimumab in the treatment of arthritis.

Authors:  Philip J Mease
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.